

DOCKET NO.: CELL-0311/PAC020USW01  
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

David Alan Owen, et al.

Confirmation No.: 2779

Application No.: 10/560,119

Group Art Unit: 1614

Filing Date: May 17, 2006

Examiner: Not Yet Assigned

For: Hydroxamate sulfonamides as CD23 shedding inhibitors

DATE OF DEPOSIT:

*September 21, 2006*

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE UNITED STATES PATENT AND  
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,  
VA 22313-1450.

*Elizabeth A. McLoud*  
TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).



In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

- ☐ Certification in Accordance with § 1.97(e) is attached; or  
☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers **1 - 15** listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).


- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: September 01, 2006

  
Jane E. Inglesse, Ph.D.  
Registration No. 48,444

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0311/ PAC020Usw01	Application No. 10/560,119
	Applicant David Alan Owen, et al.	
	Filing Date May 17, 2006	Group 1614
	Confirmation No. 2779	

**NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

1	Bonnefoy, J.-Y, <i>et al.</i> , "Functions of CD23," <i>Int. Rev. Immunol.</i> , <b>1997</b> , <i>16</i> , 113-128
2	Chomarat, P. <i>et al.</i> , "Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4," <i>Arthritis and Rheumatism</i> , <b>1993</b> , <i>36</i> , 234-242
3	Christie, G., <i>et al.</i> , "IgE secretion in attenuated by an inhibitor of proteolytic processing of CD23 (FcεRII)," <i>Eur. J. Immunol.</i> ; <b>1997</b> , <i>27</i> ; 3228-3235
4	Tsicopoulos, A., <i>et al.</i> , "The role of CD23 in allergic disease," <i>Clin. and Exp. Allergy</i> , <b>2000</b> , <i>30</i> , 602-605
5	Marolewski, A. E., <i>et al.</i> , "CD23 (FcεRII) release from cell membranes is mediated by a membrane-bound metalloprotease," <i>Biochem. J.</i> , <b>1998</b> , <i>333</i> , 573-579
6	Mayer, R. J. <i>et al.</i> , "CD23 shedding: requirements for substrate recognition and inhibition by dipeptide hydroxamic acids," <i>Inflammation Research</i> , <b>2002</b> , <i>51</i> , 085-090
7	Morré, D.J., <i>et al.</i> , "Preparation of mammalian plasma membranes by aqueous two-phase partition," <i>BioTechniques</i> , <b>1989</b> , <i>7</i> (9), 946-958
8	Sarfati, M. <i>et al.</i> , "Expression, regulation and function of human FcεRII (CD23) antigen," <i>Immunol. Res.</i> , <b>1992</b> , <i>11</i> , 260-272
9	Sutton, B.J., <i>et al.</i> , <i>Nature</i> , <b>1993</b> , <i>366</i> , 421-428

EXAMINER	/Erich Leeser/	DATE CONSIDERED	03/07/2008
----------	----------------	-----------------	------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0311/ PAC020Usw01	Application No. 10/560,119
	Applicant David Alan Owen, et al.	
	Filing Date May 17, 2006	Group 1614
	Confirmation No. 2779	

## FOREIGN PATENT DOCUMENTS

[illegible]

<b>EXAMINER</b> /Erich Leeser/	<b>DATE CONSIDERED</b> 03/07/2008
--------------------------------	-----------------------------------